Biocon (BIOCON) Q3 2026 earnings summary

Executive summary

• Completed strategic merger and integration of Biocon Biologics, creating a unified $5.5B global biopharma platform with a diversified portfolio in biosimilars, specialty generics, and high-growth metabolic and oncology segments.

• Board approved unaudited financial results and in-principle acquisition of the remaining ~2% equity in Biocon Biologics, moving towards full ownership.

• Transitioning to sustainable growth, margin expansion, and cashflow-driven value creation, with a strengthened balance sheet and improved capital structure.

Financial highlights

• Q3 FY26 operating revenue grew 9% YoY to INR 4,173 crore (₹41,730 million), led by biosimilars (+9% YoY) and generics (+24% YoY); CRDMO declined 3% YoY.

• Core EBITDA rose 21% YoY to INR 1,221 crore (29% margin); reported EBITDA at INR 951 crore (22% margin).

• Net profit before exceptional items at INR 124 crore, up 844% YoY; reported net profit at INR 144 crore, up 475% YoY; consolidated net loss for Q3 FY26 was Rs. 518 million due to exceptional items.

• Nine-month FY26 operating revenue and EBITDA up 14% and 24% YoY, respectively; net profit at INR 260 crore.

• Exceptional items, including labor code changes and transaction-related costs, significantly impacted quarterly results.

Outlook and guidance

• CapEx cycle largely complete; future investments to focus on maintenance, with annual CapEx moderating below $225M.

• Margin expansion and sustainable growth expected as operating leverage increases and new launches ramp up.

• Guidance for biosimilars margins in the mid-20s for FY26, with potential for improvement as new products scale.

• Board continues to focus on full integration of BBL and capital structure optimization.